Small nucleic acids gain momentum: leading companies go public in the capital market, domestic supply chains benefit, and capital expenditure accelerates

Innovation is the eternal main theme, and small nucleic acids are expected to become a new highlight in the pharmaceutical industry by 2026. After leading companies complete their IPOs, industry resources will accelerate to gather, and domestic supply chains are expected to benefit from the dual boost of policies and capital expenditure.

What is the underlying development logic of the small nucleic acid industry? Why are global pharmaceutical giants all focusing on the small nucleic acid field?

From the perspective of the domestic supply chain, which industry segments will benefit?